Promising Dual Immunotherapy for Anaplastic Thy...

By Rene Pretorius

January 10, 2025

We review the results from the phase 2 nonrandomized clinical trial on the clinical activity of dual immune checkpoint inhibition in aggressive thyroid cancer. The purpose of the study was to...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.